Chronic Lymphocytic Leukemia | Topics

Phase 1/2 Trial Demonstrates Activity of Pirtobrutinib in CLL, B-Cell Malignancies
April 01, 2021

Research investigating the highly selective, reversible BTK inhibitor pirtobrutinib found the drug was safe and active for treating patients with chronic lymphocytic leukemia as well as other B-cell malignancies.

Higher Overall Response Rates Observed When Adding Ublituximab to Ibrutinib Treatment for CLL
March 15, 2021

The new combination treatment of ublituximab plus ibrutinib resulted in a higher overall response rate and a tolerable safety profile for patients with relapsed or refractory high-risk CLL.

Tolerable Safety Profile, Positive Efficacy Found With Obinutuzumab Plus Chemotherapy for Patients With CLL
March 04, 2021

The GREEN trial analyzed treatment with obinutuzumab monotherapy or obinutuzumab plus chemotherapy for patients with previously untreated or relapsed/refractory chronic lymphocytic leukemia.